Literature DB >> 24647014

HIV-1 DNA levels in peripheral blood mononuclear cells and cannabis use are associated with intermittent HIV shedding in semen of men who have sex with men on successful antiretroviral regimens.

Jade Ghosn1, Marianne Leruez-Ville2, Jérôme Blanche3, Aurore Delobelle4, Céline Beaudoux4, Laurence Mascard5, Hervé Lecuyer5, Ana Canestri6, Roland Landman7, David Zucman8, Diane Ponscarme9, Agathe Rami10, Jean-Paul Viard1, Bruno Spire3, Christine Rouzioux2, Dominique Costagliola4, Marie Suzan-Monti3.   

Abstract

BACKGROUND: Few data exist on the efficacy of combined antiretroviral therapy (cART) in semen of human immunodeficiency virus type 1 (HIV-1) infected men who have sex with men (MSM) with sustained control of HIV replication in blood.
METHODS: HIV-1 infected MSM on successful cART for >6 months were enrolled. HIV-RNA was quantified in seminal plasma (spVL) and in blood plasma (bpVL) from 2 paired samples collected 4 weeks apart. Relationship between spVL and bpVL (measured by an ultrasensitive assay, LOQ 10 copies/mL), total peripheral blood mononuclear cells (PBMC)-associated HIV-DNA, sexually transmitted infections (STIs), and self-reported socio-behavioral characteristics was assessed using GEE logistic regression.
RESULTS: In total, 157 patients were included. Median time with bpVL <50 copies/mL was 3.3 years. spVL was detectable in 23/304 samples (prevalence 7.6%). Median spVL was 145 cp/mL (100-1475). spVL was detectable on the first, on the second, and on both samples in 5, 14, and 2 men, respectively. In sum, 33 individuals (21%) had STIs (asymptomatic in 24/33). Residual bpVL was undetectable by ultrasensitive assay in 225/300 samples (75%). After multivariable adjustments, PBMC-associated HIV-DNA (OR 2.6[1.2; 6.0], for HIV-DNA > 2.5 log10 cp/10(6) PBMC, P = .02), and cannabis use during sexual intercourse (OR 2.8[1.2; 6.7], P = .02) were the only factors associated significantly with spVL.
CONCLUSION: We show that HIV-RNA can be detected intermittently in semen of HIV-1 infected MSM despite successful cART. The size of blood HIV-1 reservoir predicted spVL detection. Our results indicated also that the possible effect of cannabis should be taken into account when developing prevention interventions targeted toward HIV-infected MSM on successful cART.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  compartmentalization; seminal HIV-RNA; sexual transmission; sexually transmitted infections

Mesh:

Substances:

Year:  2014        PMID: 24647014     DOI: 10.1093/cid/ciu187

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  24 in total

Review 1.  HIV treatment as prevention in men who have sex with men: examining the evidence.

Authors:  Patrick O'Byrne; Paul MacPherson
Journal:  CMAJ       Date:  2015-12-22       Impact factor: 8.262

2.  Marijuana use and viral suppression in persons receiving medical care for HIV-infection.

Authors:  Chukwuemeka N Okafor; Zhi Zhou; Larry E Burrell; Natalie E Kelso; Nicole E Whitehead; Jeffery S Harman; Christa L Cook; Robert L Cook
Journal:  Am J Drug Alcohol Abuse       Date:  2016-07-11       Impact factor: 3.829

3.  Detection of Simian Immunodeficiency Virus in Semen, Urethra, and Male Reproductive Organs during Efficient Highly Active Antiretroviral Therapy.

Authors:  G Matusali; N Dereuddre-Bosquet; A Le Tortorec; M Moreau; A-P Satie; D Mahé; P Roumaud; O Bourry; N Sylla; S Bernard-Stoecklin; A Pruvost; R Le Grand; N Dejucq-Rainsford
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

4.  The Association Between Marijuana Use and HIV Continuum of Care Outcomes: a Systematic Review.

Authors:  LaTrice Montgomery; Kara Bagot; Jennifer L Brown; Angela M Haeny
Journal:  Curr HIV/AIDS Rep       Date:  2019-02       Impact factor: 5.071

Review 5.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Authors:  Véronique Avettand-Fènoël; Laurent Hocqueloux; Jade Ghosn; Antoine Cheret; Pierre Frange; Adeline Melard; Jean-Paul Viard; Christine Rouzioux
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

6.  Daily Marijuana Use is Associated with Missed Clinic Appointments Among HIV-Infected Persons Engaged in HIV Care.

Authors:  Aaron M Kipp; Peter F Rebeiro; Bryan E Shepherd; Lauren Brinkley-Rubinstein; Megan Turner; Sally Bebawy; Timothy R Sterling; Todd Hulgan
Journal:  AIDS Behav       Date:  2017-07

7.  Self-reported Cannabis Use and Changes in Body Mass Index, CD4 T-Cell Counts, and HIV-1 RNA Suppression in Treated Persons with HIV.

Authors:  James T Lee; Lauren A Saag; Aaron M Kipp; James Logan; Bryan E Shepherd; John R Koethe; Megan Turner; Sally Bebawy; Timothy R Sterling; Todd Hulgan
Journal:  AIDS Behav       Date:  2020-04

8.  High-intensity cannabis use and HIV clinical outcomes among HIV-positive people who use illicit drugs in Vancouver, Canada.

Authors:  Stephanie Lake; Thomas Kerr; Rielle Capler; Jeannie Shoveller; Julio Montaner; M-J Milloy
Journal:  Int J Drug Policy       Date:  2017-03-21

9.  High-intensity cannabis use associated with lower plasma human immunodeficiency virus-1 RNA viral load among recently infected people who use injection drugs.

Authors:  M-J Milloy; Brandon Marshall; Thomas Kerr; Lindsey Richardson; Robert Hogg; Silvia Guillemi; Julio S G Montaner; Evan Wood
Journal:  Drug Alcohol Rev       Date:  2014-11-11

10.  Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study.

Authors:  Elodie Valade; Jean-Marc Tréluyer; Silvia M Illamola; Naïm Bouazza; Frantz Foissac; Maïlys De Sousa Mendes; Gabrielle Lui; Camille Chenevier-Gobeaux; Marie Suzan-Monti; Christine Rouzioux; Lambert Assoumou; Jean-Paul Viard; Déborah Hirt; Saïk Urien; Jade Ghosn
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.